Related Experiment Video
Updated: Feb 8, 2026
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
Design and evaluation of glomerulus mesangium-targeted PEG-PLGA nanoparticles loaded with dexamethasone acetate
Sha Li1, Ying-Chun Zeng1, Ke Peng1
1Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, 610041, Chengdu, China.
Abstract:
Mesangial proliferative glomerulonephritis (MsPGN), one of the most common glomerulonephritis pathological types, often leads to end-stage renal disease over a prolonged period. But the current treatment of MsPGN is non-specific and causes serious side effects, thus novel therapeutics and targeting strategies are urgently demanded. By combining the advantages of PEG-PLGA nanoparticles and the size selection mechanism of renal glomerulus, we designed and developed a novel PEG-PLGA nanoparticle delivery system capable of delivering dexamethasone acetate (A-DEX) into glomerular mesangium. We determined that 90 nm was the optimum size to encapsulate A-DEX for glomerular mesangium targeting based on the size-selection mechanism of glomerulus. After intravenous administration in rats, 90 nm DiD-loaded NPs were found to accumulate to a greater extent in the kidney and kidney cortex compared with the free DiD solution. The 90 nm A-DEX NPs are also more stable at room temperature and showed a sustained release pattern. In rat glomerular mesangial cells (HBZY-1) in vitro, we found that the uptake of 90 nm A-DEX NPs was both temperature-dependent and energe-dependent, and they were mostly engulfed via clathrin-dependent endocytosis pathways. In summary, we have successfully developed a glomerular mesangium-targeted PEG-PLGA NPs, which is potential for the treatment of MsPGN.
Insights
Researchers developed targeted nanoparticles for mesangial proliferative glomerulonephritis (MsPGN) treatment. These 90nm PEG-PLGA nanoparticles effectively deliver dexamethasone acetate to the glomerulus, offering a promising new therapeutic strategy for kidney disease.
Area of Science:
- Nanomedicine
- Nephrology
- Drug Delivery Systems
Background:
- Mesangial proliferative glomerulonephritis (MsPGN) is a common cause of end-stage renal disease.
- Current MsPGN treatments are non-specific and have significant side effects, necessitating novel therapeutic approaches.
- Targeted drug delivery to the glomerulus is crucial for effective MsPGN management.
Purpose of the Study:
- To design and develop a novel nanoparticle delivery system for targeted delivery of dexamethasone acetate (A-DEX) to the glomerular mesangium.
- To optimize nanoparticle size for enhanced glomerular mesangium accumulation based on renal glomerulus size-selection mechanisms.
- To evaluate the efficacy and targeting potential of A-DEX-loaded nanoparticles for MsPGN treatment.
Main Methods:
- PEG-PLGA nanoparticles encapsulating dexamethasone acetate (A-DEX) were synthesized and characterized for size and stability.
- In vivo studies in rats were conducted using DiD-loaded nanoparticles to assess kidney and kidney cortex accumulation.
- In vitro studies using rat glomerular mesangial cells (HBZY-1) investigated nanoparticle uptake mechanisms.
Main Results:
- 90nm was identified as the optimal nanoparticle size for glomerular mesangium targeting.
- Intravenously administered 90nm nanoparticles showed significantly higher accumulation in the kidney and kidney cortex compared to free drug.
- Nanoparticles exhibited stability at room temperature and a sustained drug release pattern, with uptake via clathrin-dependent endocytosis in vitro.
Conclusions:
- A novel glomerular mesangium-targeted PEG-PLGA nanoparticle system for dexamethasone acetate delivery was successfully developed.
- The 90nm nanoparticles demonstrate efficient targeting and accumulation in the kidney, indicating potential for treating MsPGN.
- This targeted delivery system offers a promising strategy to overcome the limitations of current non-specific MsPGN treatments.
Related Concept Videos
01:17Design of Columns under a Centric Load
Euler's formula is applicable under the assumption that the column is a perfect, straight, homogenous prism, and it is operating...
01:21Design of Columns under an Eccentric Load
02:01Group Design
01:24Acetals and Thioacetals as Protecting Groups for Aldehydes and Ketones
In the presence of multiple functional groups, when selective reduction of one group over the other is desired, groups like aldehydes and ketones that form acetals...
02:01Factorial Design
01:19Impact Loading
In cases of elastic deformation,...